^
    Back
    Association details:
    Biomarker:KRAS G12D
    Cancer:Ovarian Cancer
    Drug:mirdametinib (PD-0325901) (MEK inhibitor) +
    PF-04691502 (mTOR inhibitor, PI3K inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Mol Cancer Ther
    Title:

    In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer

    Excerpt:
    Combined inhibition of PI3K/mTOR (PF-04691502) and MEK (PD-0325901) leads to regression of transplanted KrasG12D; Ptendel ovarian adenocarcinomas in vivo…Combining PF-04691502 and PD-0325901 led to a greater effect than either agent alone, with striking tumor regression (>20% volume reduction) in all 9 mice (mean volume 80.7% ± 5.0 smaller on day 7 compared with day 0 tumor volume)...
    DOI:
    10.1158/1535-7163.MCT-11-0240